Zum Inhalt springen

Rhode Island Joins the Medicaid GLP-1 Cutbacks as Massachusetts Weight-Loss Use Falls 52% — October 05, 2026

05.10.2026 · 10 Min.

Shownotes

Rhode Island Medicaid stopped covering GLP-1s prescribed only for weight loss on October 1, and new Massachusetts data shows weight-loss use fell 52% after insurers pulled back. Plus Cigna employees pressing their own employer, a physician's case against the compounding market, and semaglutide's benefits across frailty levels.

In this episode
  1. Rhode Island Medicaid Ends Coverage of Wegovy,… — Inkl

    # Rhode Island Medicaid Ends Coverage of Wegovy, Zepbound, and Other GLP-1 Drugs Prescribed Only for Weight Loss Author: Cole Mercer Published: 2026-10-03T12:50:36Z Source: medicaldaily.com Language: en ## Story Rhode Island Medicaid Ends Coverage of Wegovy, Zepbound, and Other GLP-1 Drugs Prescribed Only for Weight Loss Oct 03, 08:50 am EDT [Medical…

  2. GLP-1 use for weight loss plunges 52% in Massachusetts after insurers cut coverage — Morgan Taylor

    Insurers Cut Coverage — GLP‑1 Weight‑Loss Use in Massachusetts Falls 52%, Impacting 112,000 Patients - CRBC News # Insurers Cut Coverage — GLP‑1 Weight‑Loss Use in Massachusetts Falls 52%, Impacting 112,000 Patients Morgan Taylor| The Cool Down Oct 3• 3 min read 2 Save Massachusetts saw a 52% decline in GLP‑1 use for weight loss between 2025 and Q1 2026 after multiple commercial and state…

  3. OAC Calls on Cigna to Listen to Employees and Restore GLP-1 Coverage — PR Newswire

    OAC Calls on Cigna to Listen to Employees and Restore GLP-1 Coverage # OAC Calls on Cigna to Listen to Employees and Restore GLP-1 Coverage Obesity Action Coalition Oct 02, 2026, 08:15 ET TAMPA, Fla., Oct. 2, 2026 /PRNewswire/ -- The Obesity Action Coalition (OAC) is calling on Cigna to listen to its employees and reconsider its decision to end coverage of GLP-1 medications for weight…

  4. I'm an obesity expert and can't wait for the compounding craze to stop | Fortune — Adonis Saremi

    # I'm an obesity expert and can't wait for the compounding craze to stop | Fortune Author: Adonis Saremi Published: 2026-10-03T11:30:00Z Source: fortune.com Language: en ## Story I'm an obesity expert and can't wait for the compounding craze to stop | Fortune # I’m an obesity expert and can’t wait for the compounding craze to stop By Adonis Saremi October 3, 2026, 7:30 AM ET Dr. Adonis…

  5. Semaglutide Demonstrates Benefits Across Frailty Levels | Obesity | JAMA | JAMA Network — Samantha Anderer

    Semaglutide Demonstrates Benefits Across Frailty Levels | Obesity | JAMA | JAMA Network # Semaglutide Demonstrates Benefits Across Frailty Levels Samantha Anderer Article Information Published Online: October 2, 2026 The glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide demonstrated safety and efficacy regardless of frailty status, a study published in JAMA Cardiology…

Daily TopFive for GLP-1 Daily. Links above go to the original articles. Follow and rate GLP-1 Daily on Apple Podcasts. Feedback? Email [email protected].

Alle Folgen von GLP-1 Daily: Ozempic & Wegovy News

Einstellungen

Darstellung

Sprache

Bestimmt, welche Sender dir auf der Startseite zuerst gezeigt werden.

Verlauf

Zuletzt gehörte Sender und Folgen und deine letzten Suchen liegen nur in diesem Browser.

Hinweise

Ein kurzer Hinweis, wenn ein Podcast, dem du folgst, eine neue Folge hat. Einzelne Podcasts stellst du über die Glocke auf ihrer Seite ab.

Konto

Favoriten speichern – in der App und auf der Website.

Tastenkürzel

/
Suche öffnen
Leertaste
Abspielen oder anhalten
← →
Im Player: 15 s zurück, 30 s vor (Folgen) · im Regal: nächste Kachel
↑ ↓
Im Regal: Ziel innerhalb der Kachel
Pos1 / Ende
Im Regal: erste bzw. letzte Kachel
Esc
Fenster oder Menü schließen
?
Diese Übersicht
Läuft gerade

Zur Senderseite

Als Nächstes

    Folgen mit „Als Nächstes“ vormerken – sie laufen nach der aktuellen Folge.